Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening.

Autor: Schaal W; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.; Pincer Bio AB, Uppsala, Sweden., Ameur A; Pincer Bio AB, Uppsala, Sweden.; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Olsson-Strömberg U; Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden., Hermanson M; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Cavelier L; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Spjuth O; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.; Pincer Bio AB, Uppsala, Sweden.
Jazyk: angličtina
Zdroj: Cancer informatics [Cancer Inform] 2022 Jul 15; Vol. 21, pp. 11769351221110872. Date of Electronic Publication: 2022 Jul 15 (Print Publication: 2022).
DOI: 10.1177/11769351221110872
Abstrakt: Objective: The aim of this project was to implement long-read sequencing for BCR-ABL1 TKI resistance mutation screening in a clinical setting for patients undergoing treatment for chronic myeloid leukemia.
Materials and Methods: Processes were established for registering and transferring samples from the clinic to an academic sequencing facility for long-read sequencing. An automated analysis pipeline for detecting mutations was established, and an information system was implemented comprising features for data management, analysis and visualization. Clinical validation was performed by identifying BCR-ABL1 TKI resistance mutations by Sanger and long-read sequencing in parallel. The developed software is available as open source via GitHub at https://github.com/pharmbio/clamp.
Results: The information system enabled traceable transfer of samples from the clinic to the sequencing facility, robust and automated analysis of the long-read sequence data, and communication of results from sequence analysis in a reporting format that could be easily interpreted and acted upon by clinical experts. In a validation study, all 17 resistance mutations found by Sanger sequencing were also detected by long-read sequencing. An additional 16 mutations were found only by long-read sequencing, all of them with frequencies below the limit of detection for Sanger sequencing. The clonal distributions of co-existing mutations were automatically resolved through the long-read data analysis. After the implementation and validation, the clinical laboratory switched their routine protocol from using Sanger to long-read sequencing for this application.
Conclusions: Long-read sequencing delivers results with higher sensitivity compared to Sanger sequencing and enables earlier detection of emerging TKI resistance mutations. The developed processes, analysis workflow, and software components lower barriers for adoption and could be extended to other applications.
Competing Interests: Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Authors WS, AA, and OS are involved with Pincer Bio AB, a company formed as a result of the work presented herein to further develop and distribute LR-SMS analysis software.
(© The Author(s) 2022.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje